- The FDA has given Bayer and Onyx Pharmaceuticals (NASDAQ:ONXX) priority review for their application to use their Nexavar (sorafenib) drug against a difficult-to-treat type of thyroid cancer.
- The designation means that the FDA will endeavor to complete the review within six months rather than nine.
- Nexavar is already authorized for use against liver and kidney tumors, and it is being trialled for breast cancer. (PR)